1800 244 735

Helpline (02) 9874 9777

HD Therapeutics Conference 2012 Updates: Day 1

Our first daily report from the annual Huntington’s Disease Therapeutics Conference in Palm Springs, California. We’ll be bringing you live updates via Twitter over the next two days. You can tweet @HDBuzzFeed or email [email protected] with your questions, comments and queries.

Monday, February 27, 2012

17:02 – The Huntington’s Disease Therapeutics Conference has officially begun. Ed and Jeff will be tweeting every day

17:06 – Dr Robert Pacifici opens the conference. Reviews the many ‘impossible’ questions science has already answered in HD

17:00 – CHDI Chief Scientific Officer Robert Pacifici asks – what are the remaining provocative questions in Huntington’s Disease research?

Tuesday, February 28, 2012

9:05 – Good morning from Palm Springs. The science sessions of the HD Therapeutics conference are about to begin.

9:20 – The first session is systems biology – using powerful technology to collect and analyse huge amounts of data to help understand HD

9:25 – Leroy Hood (Institute for Systems Biology): scientists should work with mathematicians, engineers, physicists for best chance of progress

9:40 – Hood: we should be able to develop chemical ‘fingerprints’ in blood to diagnose and monitor brain disease.

9:47 – Hood: we can now sequence people’s entire genomes to look for genes that might affect when and how Huntington’s affects people

10:05 – Keith Elliston is CHDI’s new Vice President of ‘Systems Biology’ – or the science of understanding entire biological systems.

10:00 – Elliston: All the changes we see in HD patients are due to a single mutation, which should help us understand the disease.

10:20 – Elliston: CHDI’s strategy for developing HD treatments will extensively use systems biology and the deep understanding it can bring

10:22 – CHDI is the non-profit biotech company behind the conference and biggest HD research organisation. We’re interviewing their top scientists later.

10:24 – Elliston: there is no such thing as a perfect disease model. We need to take the best from each model – and remember patients

10:39 – CHDI is developing a ‘map’ of all the changes in HD, starting with the function of synapses – chemical connections between neurons

10:43 – Elliston: Working to ensure that HD researchers have access to as much information as possible, rather than keeping things private

11:30 – Jim Gusella (Massachusetts General Hospital in Boston): the smaller of a person’s two CAG repeat lengths does not affect disease onset. See our article on this “New analysis suggests ‘small’ CAG length doesn’t matter after all”

11:58 – Gusella: His team is looking at the whole genome of HD patients to try and find other genes that might change HD symptoms.

12:26 – Gusella: some of the genes described to change the age that people experience HD symptoms might be wrong, new studies are on going

12:33 – Hanchuan Peng (Howard Hughes Medical Institute) studies the shape of brains at the level of individual cells. Could this help HD research?

14:31 – Melissa Moore (University of Massachusetts Medical School): The RNA ‘message molecule’ that tells cells to make Huntingtin protein might cause problems in its own right

14:33 – Moore: cells have quality control mechanisms for RNA message molecules. Could we enhance these to reduce damage in HD?

14:51 – Moore: RNA drugs currently being tested in cystic fibrosis/Duchenne muscular dystrophy might prove useful for HD

15:01 – Moore: lots of possible ways that drugs might be able to reduce production of Huntingtin protein. Gene silencing by the back door?

15:22 – Naoko Tanese (New York University School of Medicine): New role for the Huntingtin protein. It acts like a bus, carrying RNA molecules around the cell

15:36 – Tanese: one of the RNA molecules that the protein carries around the cell is the Huntingtin RNA. Huntingtin drives its own bus!

16:07 – Lisa Ellerby (The Buck Institute for Age Research) studies chemical modification of the Huntingtin protein – tiny tags that change its location and function

16:17 – Ellerby: Putting more ‘phospho’ groups on the Huntingtin protein might make it less toxic. But are there drugs that can do this?

16:37 – Dimitri Krainc (Massachusetts General Hospital): studies modification of the Huntingtin protein that direct it to the cells garbage can, clearing it from cells

16:53 – Krainc: Drugs developed by CHDI to increase traffic of the mutant Huntingtin protein to the trash work in cells

17:19 – Marcy MacDonald (Massachusetts General Hospital) and her group are making buckets of purified Huntingtin protein to study – tough work bit very useful for research

17:36 – MacDonald: Adding ‘phospho’ groups to the Huntingtin protein might be good or bad, we need more information to decide what to target

Sunset conclusions

The morning session reminded us that we must remember that virtually every cell and molecule in our bodies is connected to every other in some way. Focusing exclusively on changing one thing without considering knock-on effects of those changes could lead to unpredictable results. In the afternoon, we heard some intriguing ideas of how cells produce and ‘tag’ the mutant huntingtin protein – the molecule at the heart of the network of damage in HD – and how we might be able to fine tune those changes to our advantage.

Latest Research Articles

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Published date: 9 December, 2022

The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment in Huntington’s disease (HD). This news comes following recent bad news about side effects of branaplam in HD patients, being tested in the VIBRANT-HD clinical trial, dosing of which was ... Read more

Update on the PTC Therapeutics PIVOT-HD Trial

Published date: 2 November, 2022

Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of different (and confusing!) headlines about the pause in recruitment. In this article, we will lay out what is going on and what this announcement means. What is the aim of ... Read more

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Published date: 30 September, 2022

In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. First, the pharmaceutical company Roche announced plans for a new clinical trial of tominersen. Then, the genetic medicines company Wave Life Sciences shared early data showing that its ... Read more

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Published date: 1 September, 2022

Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about today is from Anastasia Khvorova, who will be telling us about her teams work on lowering of Huntingtin using technology called RNAi. One of the problems in studying drug delivery ... Read more